These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23838819)

  • 1. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R; Sprietsma L; Rudnick DA
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S; Baumann U
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTBC and alkaptonuria.
    Anikster Y; Nyhan WL; Gahl WA
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corneal opacities associated with NTBC treatment.
    Ahmad S; Teckman JH; Lueder GT
    Am J Ophthalmol; 2002 Aug; 134(2):266-8. PubMed ID: 12140036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.
    Schauwvlieghe PP; Jaeken J; Kestelyn P; Claerhout I
    Cornea; 2013 Jan; 32(1):91-4. PubMed ID: 22495034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
    Gissen P; Preece MA; Willshaw HA; McKiernan PJ
    J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nontransplant treatment of tyrosinemia.
    Holme E; Lindstedt S
    Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN; Venugopalan P
    Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
    László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M
    Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
    Al-Dhalimy M; Overturf K; Finegold M; Grompe M
    Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
    Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
    Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
    Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
    J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
    De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
    Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
    [No Abstract]   [Full Text] [Related]  

  • 18. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.
    Hanauske-Abel HM; Popowicz A; Remotti H; Newfield RS; Levy J
    J Pediatr Gastroenterol Nutr; 2002 Jul; 35(1):73-8. PubMed ID: 12142814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
    van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
    Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
    Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.